Ligand signs deal with start-up CURx to develop first topiramate injection for epilepsy

15 August 2013

US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has entered a global license agreement with start-up CURx Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

Currently, topiramate is only available in oral formulations, and is sold by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (NYSE: JN), under the trade name Topamax.

Under the terms of the agreement, Ligand will be eligible to receive more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical